Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05522153 | Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study | PHASE1 | COMPLETED | 61 | — | — | May 1, 2021 | Jun 8, 2023 | Sep 19, 2024 | 1 | United States |
Calculated on standard hospital protocol
| Arm | Type | Description |
|---|---|---|
| Arista group | EXPERIMENTAL | this group of randomized patients will receive 5 grams of arista hemostatic powder intra-operatively in their wound in addition to 1 gram of IV transexemic acid prior to incision |
| control group | NO_INTERVENTION | this group of randomized patients will receive just the 1 gram of IV transexemic acid prior to incision |
| Name | Type | Description |
|---|---|---|
| Arista | DRUG | hemostatic powder |
Inclusion Criteria: * • They willingly desire to participate and signed the informed consent * Are between the ages of 18 and 100 years of age * Have the mental capacity to provide consent * Are undergoing a primary unilateral total knee arthroplasty Exclusion Criteria: * • allergy to Aris...